Subcutaneous Tocilizumab for Thyroid Eye Disease: Simplified Dosing and Delivery

Intravenous tocilizumab has been demonstrated to be an effective disease modifying agent in the treatment of moderate to severe active thyroid eye disease. The authors describe 2 patients treated with tocilizumab using home subcutaneous administration over an accelerated, biweekly course. Both patie...

Full description

Saved in:

Bibliographic Details
Published in:	Ophthalmic plastic and reconstructive surgery Vol. 35; no. 3; pp. e64 - e66
Main Authors:	Copperman, Thomas, Idowu, Oluwatobi O, Kersten, Robert C, Vagefi, M Reza
Format:	Journal Article
Language:	English
Published:	United States 01-05-2019
Subjects:	Aged Antibodies, Monoclonal, Humanized - administration & dosage Dose-Response Relationship, Drug Female Follow-Up Studies Graves Ophthalmopathy - diagnosis Graves Ophthalmopathy - drug therapy Humans Injections, Subcutaneous Male Radionuclide Imaging
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Intravenous tocilizumab has been demonstrated to be an effective disease modifying agent in the treatment of moderate to severe active thyroid eye disease. The authors describe 2 patients treated with tocilizumab using home subcutaneous administration over an accelerated, biweekly course. Both patients exhibited improvement in thyroid eye disease clinical activity and proptosis.
Bibliography:	ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3
ISSN:	0740-9303 1537-2677
DOI:	10.1097/IOP.0000000000001346